UA116876C2 - Спосіб одержання хінолінових похідних - Google Patents

Спосіб одержання хінолінових похідних

Info

Publication number
UA116876C2
UA116876C2 UAA201405355A UAA201405355A UA116876C2 UA 116876 C2 UA116876 C2 UA 116876C2 UA A201405355 A UAA201405355 A UA A201405355A UA A201405355 A UAA201405355 A UA A201405355A UA 116876 C2 UA116876 C2 UA 116876C2
Authority
UA
Ukraine
Prior art keywords
formula
compound
embed isisserver
quinoline derivatives
аlкуl
Prior art date
Application number
UAA201405355A
Other languages
English (en)
Ukrainian (uk)
Inventor
Джо Енн Уілсон
Срірам Наганатхан
Меттью Пфайффер
Ніл Г. Андерсен
Original Assignee
Екселіксіс, Інк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Екселіксіс, Інк. filed Critical Екселіксіс, Інк.
Publication of UA116876C2 publication Critical patent/UA116876C2/uk

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20Oxygen atoms
    • C07D215/22Oxygen atoms attached in position 2 or 4
    • C07D215/233Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 4
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C231/00Preparation of carboxylic acid amides
    • C07C231/02Preparation of carboxylic acid amides from carboxylic acids or from esters, anhydrides, or halides thereof by reaction with ammonia or amines
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00Carboxylic acid amides
    • C07C233/57Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C233/58Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00Carboxylic acid amides
    • C07C233/57Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C233/59Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by halogen atoms or by nitro or nitroso groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72Quinazolines; Hydrogenated quinazolines
    • C07D239/86Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88Oxygen atoms
    • C07D239/90Oxygen atoms with acyclic radicals attached in position 2 or 3

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Quinoline Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
UAA201405355A 2011-10-20 2012-10-22 Спосіб одержання хінолінових похідних UA116876C2 (uk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161549312P 2011-10-20 2011-10-20
PCT/US2012/061320 WO2013059788A1 (en) 2011-10-20 2012-10-22 Process for preparing quinoline derivatives

Publications (1)

Publication Number Publication Date
UA116876C2 true UA116876C2 (uk) 2018-05-25

Family

ID=47146705

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201405355A UA116876C2 (uk) 2011-10-20 2012-10-22 Спосіб одержання хінолінових похідних

Country Status (23)

Country Link
US (3) US9365516B2 (https=)
EP (1) EP2768796B1 (https=)
JP (2) JP6208140B2 (https=)
KR (1) KR102075371B1 (https=)
CN (2) CN104395284A (https=)
AR (1) AR088483A1 (https=)
AU (2) AU2012325768B2 (https=)
BR (1) BR112014009302B1 (https=)
CA (1) CA2852771C (https=)
DK (1) DK2768796T3 (https=)
EA (1) EA031485B1 (https=)
ES (1) ES2765013T3 (https=)
GE (1) GEP20207110B (https=)
HU (1) HUE048023T2 (https=)
IL (1) IL232139A (https=)
IN (1) IN2014CN02971A (https=)
MX (1) MX343288B (https=)
PL (1) PL2768796T3 (https=)
PT (1) PT2768796T (https=)
TW (2) TWI642650B (https=)
UA (1) UA116876C2 (https=)
WO (1) WO2013059788A1 (https=)
ZA (1) ZA201402579B (https=)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2593090B1 (en) 2010-07-16 2021-10-13 Exelixis, Inc. C-met modulator pharmaceutical compositions
CA2812750C (en) 2010-09-27 2020-10-06 Exelixis, Inc. Dual inhibitors of met and vegf for the treatment of castration-resistant prostate cancer and osteoblastic bone metastases
JP2014505109A (ja) 2011-02-10 2014-02-27 エクセリクシス, インク. キノリン化合物およびそのような化合物を含有する医薬組成物の調製方法
US20120252840A1 (en) 2011-04-04 2012-10-04 Exelixis, Inc. Method of Treating Cancer
KR20140025496A (ko) 2011-05-02 2014-03-04 엑셀리시스, 인코포레이티드 암 및 뼈 암 통증의 치료방법
GEP201606523B (en) 2011-09-22 2016-08-10 Exelixis Inc Method for treating osteoporosis
DK2768796T3 (da) * 2011-10-20 2020-02-24 Exelixis Inc Fremgangsmåde til fremstilling af quinolin-derivater
JP2015515988A (ja) 2012-05-02 2015-06-04 エクセリクシス, インク. 溶骨性骨転移を治療するためのmet−vegf二重調節剤
AU2014232714B2 (en) 2013-03-15 2018-07-19 Exelixis, Inc. Metabolites of N-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-n'-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide
EP2981263B1 (en) 2013-04-04 2022-06-29 Exelixis, Inc. Cabozantinib dosage form and use in the treatment of cancer
CN104649969B (zh) * 2013-11-22 2019-02-12 广东东阳光药业有限公司 一种替尼类药物的盐及其制备方法
KR102354963B1 (ko) 2014-02-14 2022-01-21 엑셀리시스, 인코포레이티드 N-{4-[(6,7-다이메톡시퀴놀린-4-일)옥시]페닐}-n'-(4-플루오로페닐) 사이클로프로판-1,1-다이카복스아마이드의 결정질 고체 형태, 제조 방법 및 사용 방법
EA201691850A1 (ru) 2014-03-17 2016-12-30 Экселиксис, Инк. Дозирование составов, содержащих кабозантиниб
CN104788372B (zh) * 2014-07-25 2018-01-30 上海圣考医药科技有限公司 一种氘代卡博替尼衍生物、其制备方法、应用及其中间体
ES2929888T3 (es) 2014-07-31 2022-12-02 Exelixis Inc Procedimiento para preparar cabozantinib marcado con flúor 18 y sus análogos
BR112017002318A2 (pt) 2014-08-05 2018-07-17 Exelixis, Inc. combinações de fármacos para tratar mieloma múltiplo.
CN108026035B (zh) * 2015-09-02 2021-03-30 陈昆锋 具有蛋白酪氨酸磷酸酶shp-1激动剂活性的化合物
RU2748549C2 (ru) 2016-04-15 2021-05-26 Экселиксис, Инк. Способ лечения почечно-клеточного рака с использованием n-(4-(6,7-диметоксихинолин-4-илокси)фенил)-n'-(4-фторфенил)циклопропан-1,1-дикарбоксамида, (2s)-гидроксибутандиоата
CN109836382B (zh) * 2017-11-29 2021-11-05 江苏豪森药业集团有限公司 苹果酸卡博替尼及其中间体的制备方法
UA128476C2 (uk) 2018-01-26 2024-07-24 Екселіксіс, Інк. Сполуки для лікування кіназозалежних розладів
CN113292537B (zh) 2018-06-15 2024-04-05 汉达癌症医药责任有限公司 激酶抑制剂的盐类及其组合物
TWI887405B (zh) 2020-04-30 2025-06-21 美商艾克塞里克斯公司 製備激酶抑制劑之方法
CN112142619B (zh) * 2020-10-20 2023-01-10 浙江工业大学 一种1,1-环丙烷二羧酸酰胺类化合物及其制备方法和应用
US20240190825A1 (en) * 2021-03-24 2024-06-13 Biocon Limited Process for preparation of cabozantinib
AU2023384196A1 (en) * 2022-11-25 2025-06-12 Msn Laboratories Private Limited, R&D Center Crystalline forms of n-(4-(6,7-dimethoxyquinolin-4-yloxy)phenyl)-n'-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide fumarate and process for its preparation
TW202444365A (zh) 2023-01-31 2024-11-16 漢達生技醫藥股份有限公司 改良之卡博替尼組合物及其使用方法

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2213661E (pt) 2003-09-26 2011-12-15 Exelixis Inc Moduladores de c-met e métodos de uso
CA2572331A1 (en) * 2004-07-02 2006-02-09 Exelixis, Inc. C-met modulators and method of use
US20080161305A1 (en) 2005-04-06 2008-07-03 Exelixis, Inc. C-Met Modulators and Methods of Use
WO2008076415A1 (en) 2006-12-14 2008-06-26 Exelixis, Inc. Methods of using mek inhibitors
UY31800A (es) 2008-05-05 2009-11-10 Smithkline Beckman Corp Metodo de tratamiento de cancer usando un inhibidor de cmet y axl y un inhibidor de erbb
US8445509B2 (en) * 2008-05-08 2013-05-21 Takeda Pharmaceutical Company Limited Fused heterocyclic derivatives and use thereof
UY32142A (es) * 2008-09-26 2010-05-31 Smithkline Beckman Corp Preparación de una quinoliniloxidifenilciclopropanodicarboxamida
US20130197230A1 (en) * 2008-11-13 2013-08-01 Jo Ann Wilson Methods of preparing quinoline derivatives
WO2010065838A1 (en) 2008-12-04 2010-06-10 Exelixis, Inc. Methods of preparing quinoline derivatives
SG173014A1 (en) 2009-01-16 2011-08-29 Exelixis Inc Malate salt of n- (4- { [ 6, 7-bis (methyloxy) quin0lin-4-yl] oxy}phenyl)-n' - (4 -fluorophenyl) cyclopropane-1,1-dicarboxamide, and crystalline forms therof for the treatment of cancer
JP2012533570A (ja) 2009-07-17 2012-12-27 エグゼリクシス, インコーポレイテッド N−[3−フルオロ−4−({6−(メチルオキシ)−7−[(3−モルホリン−4−イルプロピル)オキシ]−キノリン−4−イル}オキシ)フェニル]−n’−(4−フルオロフェニル)シクロプロパン−1,1−ジカルボキサミドの結晶形
UA108618C2 (uk) 2009-08-07 2015-05-25 Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
CA2792852A1 (en) 2010-03-12 2011-09-15 Exelixis, Inc. Hydrated crystalline forms of n-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]-quinolin-4-yl}oxy)phenyl]-n'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide
US20120070368A1 (en) 2010-04-16 2012-03-22 Exelixis, Inc. Methods of Using C-Met Modulators
EP2593090B1 (en) 2010-07-16 2021-10-13 Exelixis, Inc. C-met modulator pharmaceutical compositions
EP2593091A1 (en) 2010-07-16 2013-05-22 Exelixis, Inc. C-met modulator pharmaceutical compositions
EP2621483A1 (en) 2010-09-27 2013-08-07 Exelixis, Inc. Dual inhibitors of met and vegf for the treatment of castration resistant prostate cancer and osteoblastic bone metastases
CA2812750C (en) 2010-09-27 2020-10-06 Exelixis, Inc. Dual inhibitors of met and vegf for the treatment of castration-resistant prostate cancer and osteoblastic bone metastases
AU2011307306A1 (en) 2010-09-27 2013-05-02 Exelixis, Inc. Dual inhibitors of MET and VEGF for the treatment of castration resistant prostate cancer and osteoblastic bone metastases
WO2012071321A1 (en) 2010-11-22 2012-05-31 Glaxosmithkline Llc Method of treating cancer
JP2014505109A (ja) 2011-02-10 2014-02-27 エクセリクシス, インク. キノリン化合物およびそのような化合物を含有する医薬組成物の調製方法
US20120252840A1 (en) 2011-04-04 2012-10-04 Exelixis, Inc. Method of Treating Cancer
KR20140025496A (ko) 2011-05-02 2014-03-04 엑셀리시스, 인코포레이티드 암 및 뼈 암 통증의 치료방법
TW201306842A (zh) 2011-06-15 2013-02-16 Exelixis Inc 使用pi3k/mtor吡啶並嘧啶酮抑制劑及苯達莫司汀及/或利妥昔單抗治療惡性血液疾病之組合療法
GEP201606523B (en) 2011-09-22 2016-08-10 Exelixis Inc Method for treating osteoporosis
DK2768796T3 (da) * 2011-10-20 2020-02-24 Exelixis Inc Fremgangsmåde til fremstilling af quinolin-derivater
JP2014532766A (ja) 2011-11-08 2014-12-08 エクセリクシス, インク. 癌を治療する、met及びvegfの二重阻害剤
JP2015515988A (ja) 2012-05-02 2015-06-04 エクセリクシス, インク. 溶骨性骨転移を治療するためのmet−vegf二重調節剤
CN114129566A (zh) 2012-09-07 2022-03-04 埃克塞里艾克西斯公司 用于治疗肺腺癌的met、vegfr和ret的抑制剂

Also Published As

Publication number Publication date
HK1201517A1 (en) 2015-09-04
JP2017222648A (ja) 2017-12-21
GEP20207110B (en) 2020-05-25
IN2014CN02971A (https=) 2015-07-03
EA201490831A1 (ru) 2014-09-30
AU2012325768B2 (en) 2017-08-10
US20160229805A1 (en) 2016-08-11
KR102075371B1 (ko) 2020-02-10
GEAP201913471A (en) 2019-10-25
ES2765013T3 (es) 2020-06-05
EP2768796B1 (en) 2019-11-20
CA2852771A1 (en) 2013-04-25
PT2768796T (pt) 2020-02-21
TWI642650B (zh) 2018-12-01
BR112014009302A2 (pt) 2017-05-23
IL232139A0 (en) 2014-05-28
PL2768796T3 (pl) 2020-05-18
EP2768796A1 (en) 2014-08-27
TW201731812A (zh) 2017-09-16
WO2013059788A1 (en) 2013-04-25
HUE048023T2 (hu) 2020-05-28
ZA201402579B (en) 2015-03-25
AU2017254982A1 (en) 2017-11-23
TW201321342A (zh) 2013-06-01
CA2852771C (en) 2019-11-26
JP2014530880A (ja) 2014-11-20
CN104395284A (zh) 2015-03-04
JP6208140B2 (ja) 2017-10-04
EA031485B1 (ru) 2019-01-31
MX2014004583A (es) 2014-10-06
US9365516B2 (en) 2016-06-14
CN110511158A (zh) 2019-11-29
TWI619694B (zh) 2018-04-01
AR088483A1 (es) 2014-06-11
NZ624328A (en) 2016-10-28
US9969692B2 (en) 2018-05-15
NZ723880A (en) 2018-03-23
DK2768796T3 (da) 2020-02-24
AU2012325768A1 (en) 2014-05-22
US20140256938A1 (en) 2014-09-11
IL232139A (en) 2017-11-30
KR20140088874A (ko) 2014-07-11
MX343288B (es) 2016-11-01
BR112014009302B1 (pt) 2020-04-28
US20180230100A1 (en) 2018-08-16

Similar Documents

Publication Publication Date Title
UA116876C2 (uk) Спосіб одержання хінолінових похідних
MX2014006992A (es) Disales de acido malonico y metodo para preparar dihaluros de malonilo.
MX2018007106A (es) Metodo de produccion de un derivado de amida aromatica.
PH12016502334B1 (en) Method for producing fused heterocyclic compound
NZ600119A (en) Process and intermediates for the preparation of 5-biphenyl-4-yl-2-methylpentanoic acid derivatives
PH12015501226A1 (en) Crystalline 6,7-unsaturated-7-carbamoyl morphinane derivative, and method for producing the same
MX347564B (es) Proceso para la preparacion de n-metoxi-[1-metil-2-feniletil]amida s del acido 3-difluorometil-1-metil-1h-pirazol-4-carboxilico sustituidas con fenilo.
NZ601805A (en) Method for preparing tetrazole methanesulfonic acid salts, and novel compound used in same
MX2010003148A (es) Procedimiento para la preparacion de diamidas de acido sulfonico.
EP2665705A4 (en) PROCESS FOR THE IMPROVED PREPARATION OF SUCCINIMIDE COMPLEXES OF MOLYBDENUM OF LOW MOLECULAR WEIGHT
MX2013008595A (es) Procedimiento mejorado para la preparacion de 2,2-difluoroetilamina.
MX2014003638A (es) Cristal de hidrato 5-hidroxi-1h-imidazol-4-carboxamida-3/4, metodo para producir el mismo y cristal de hidrato de 5-hidroxi-1h-imidazol-4-carboxamida.
WO2010003704A3 (en) Process for making 1-hydroxyalkylidene-1,1-biphosphonic acids
TN2014000329A1 (en) Method for preparing compound by novel michael addition reaction using water or various acids as additive
MX361998B (es) Procedimiento de preparacion de derivados de acido 4-haloalquil-3-mercapto-2 sustituido-hidroxibenzoico.
IN2012DN00361A (https=)
SE1100784A1 (sv) Ny fosfatförening
MX349740B (es) Proceso para la preparacion de fenilpropanonas sustituidas.
MX379419B (es) Proceso para preparar compuestos de aminotioléster y sus sales.
UA113067C2 (xx) Спосіб одержання хінолінкарбонової кислоти
IN2014CN04123A (https=)
BR112013018809A8 (pt) Processo para produção de derivados de ácido amidocarboxílico aromático
GEP20156350B (en) New process for synthesis of ivabradine and their additional salts with pharmaceutically acceptable acid
MX2014008995A (es) Compuesto novedoso de ester de acido acetico o una sal del mismo.
IN2014DN07014A (https=)